MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients

Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
5018
Registration Number
NCT02242851

Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort

Phase 2
Completed
Conditions
Colic
Interventions
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2017-12-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
527
Registration Number
NCT02242292

Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
95
Registration Number
NCT02242240

Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure

Completed
Conditions
Hypertension
Interventions
Drug: MicardisPlus®
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1527
Registration Number
NCT02242864

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
13248
Registration Number
NCT02242383

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Low dose of telmisartan
Drug: High dose of telmisartan
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3045
Registration Number
NCT02242370

Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2017-12-28
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
77
Registration Number
NCT02242344

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

Phase 3
Completed
Conditions
Abdominal Pain
Interventions
Drug: Placebo
First Posted Date
2014-09-17
Last Posted Date
2017-07-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
302
Registration Number
NCT02242305

Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure

Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
19805
Registration Number
NCT02242331

Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo (HandiHaler®)
Drug: Placebo (Diskus®)
First Posted Date
2014-09-17
Last Posted Date
2014-09-17
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
111
Registration Number
NCT02242227
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy